14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HQL vs BTO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, John Hancock Financial Opportunities Fund (BTO) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). HQL carries a Unified Composite Score of 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin), whereas BTO carries 43.7/100 (HOLD) at $37.34 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While HQL currently prints a higher short-term Unified Composite Score (46.0/100 HOLD vs. BTO 43.7/100 HOLD), BTO captures the overall institutional head-to-head verdict (3–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile BTO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HQL vs BTO. Trailing 12-month operating profitability (HQL N/A vs BTO N/A) and valuation multiples (HQL N/M vs BTO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $704.9M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HQL vs BTO Key Questions & Quantitative Answers
As of Nov 16, 2026, John Hancock Financial Opportunities Fund (BTO) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). HQL carries a Unified Composite Score of 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin), whereas BTO carries 43.7/100 (HOLD) at $37.34 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While HQL currently prints a higher short-term Unified Composite Score (46.0/100 HOLD vs. BTO 43.7/100 HOLD), BTO captures the overall institutional head-to-head verdict (3–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile BTO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BTO leads the Growth & Scale pillar: HQL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BTO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HQL generates N/A in USD-normalized revenue versus N/A for BTO. In operating R&D and SG&A reinvestment, HQL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BTO.
HQL and BTO trade at balanced relative valuation multiples. HQL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQL (N/A ROE) versus BTO (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, HQL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 39% Vol realized risk). By comparison, BTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 18% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.